The medical sector can provide a defensive hedge against economic uncertainty, and investors may be eyeing AbbVie (ABBV) and HCA Healthcare (HCA) stock ahead of their Q1 reports on Friday, April 25.

We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where ...

Janelle Zeihen worried she'd have to file for bankruptcy after learning she owed $250,000 for her Crohn's disease treatment.

Investors will likely focus on the sales performance of AbbVie's blockbuster immunology drugs, Rinvoq and Skyrizi, when it ...

Passive income is essential in retirement, but building a dependable stream isn't easy. Fortunately, top-tier dividend stocks ...

AbbVie may be setting its sights on 2026, but analysts are already smitten with its present-day promise. Cantor Fitzgerald ...

Paul Stoffels left his perch as J&J’s chief scientific officer in 2022 to replace Galapagos’ founding CEO Onno van de Stolpe, ...

Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major ...

While pharmaceuticals have so far been spared from import taxes, Trump has vowed to impose a “major” tariff on the sector ...

Galapagos (Euronext: GLPG) has appointed Henry Gosebruch as chief executive of its upcoming oncology spin-off, marking a ...

The first quarter of 2025 will be remembered for rapid change. U.S. presidential transitions typically focus on achieving one ...

Mr. Gosebruch was most recently President and Chief Executive Officer at Neumora (NASDAQ: NMRA), a clinical-stage biopharmaceutical company focused on redefining neuroscience drug development. He ...